<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949038</url>
  </required_header>
  <id_info>
    <org_study_id>391009</org_study_id>
    <nct_id>NCT01949038</nct_id>
  </id_info>
  <brief_title>Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy</brief_title>
  <official_title>Comparison Between Sublingual and Oral Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnostic esophagogastroduodenoscopy is an uncomfortable and stressful procedure for most of
      the patients. Various methods are available for sedation during this procedure. Because of
      some side effects related to intravenous administration of sedatives, oral administration of
      these drugs is under attention. Alprazolam is a benzodiazepine which is used mainly in
      treatment of anxiety. Hence, we determine the efficacy of oral and sublingual alprazolam as
      for sedation during this procedure. We hypothesize that sublingual alprazolam is more
      effective than that oral form and both forms more effective than placebo in reducing anxiety
      and pain/discomfort related to the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure related pain/discomfort</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <description>Procedure related pain/discomfort is assessed by patients on a 11-point numeric rating scales after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-procedure anxiety</measure>
    <time_frame>Before and 30 minutes after medication</time_frame>
    <description>Procedure related anxiety is assessed by patients on a 11-point numeric rating scales before and 30 minutes after the medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <description>Procedure related patients' satisfaction is assessed by patients on a 11-point numeric rating scales after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <description>Compliance is assessed by patients from no compliance (0) to excellent compliance (4) after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the procedure</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <description>Duration of the procedure is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <description>Any side effects attributed to alprazolam is assessed Within the first one hour after the procedure.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Diagnostic Esophagogastroduodenoscopy</condition>
  <arm_group>
    <arm_group_label>Oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive one oral dose of placebo least 30 minutes before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sublingual placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive one oral dose of placebo at least 30 minutes before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sublingual alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral alprazolam</intervention_name>
    <arm_group_label>Oral alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual alprazolam</intervention_name>
    <arm_group_label>Sublingual alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <arm_group_label>Oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual placebo</intervention_name>
    <arm_group_label>Sublingual placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referring for upper GI endoscopy

          -  Age 18 to 65 years

          -  First experience of upper GI endoscopy

          -  Class I or II of American Anesthesiology Association

          -  Willingness to participate

        Exclusion Criteria:

          -  Severe psychiatric, neurological, cardio-vascular, or renal disorders

          -  History of allergy or intolerance to benzodiazepines or lidocaine

          -  History of upper GI surgery

          -  Pregnancy or lactation

          -  GI anomalia during endoscopy

          -  Need for therapeutic procedures during endoscopy

          -  Active bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Shavakhi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Outpatient Clinic of Gastroenterology</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Hedenbro JL, Ekelund M, Aberg T, Lindblom A. Oral sedation for diagnostic upper endoscopy. Endoscopy. 1991 Jan;23(1):8-10.</citation>
    <PMID>2009843</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>October 16, 2013</last_update_submitted>
  <last_update_submitted_qc>October 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ali Gholamrezaei</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Discomfort</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Satisfaction</keyword>
  <keyword>Compliance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

